Recent articles
Here's Why Chemours Stock Fell 20.5% in July
Investors were anticipating weak second-quarter 2019 operating results. They were right.
Here's Why Tellurian Stock Dropped 21.4% in July
A Wall Street analyst soured on the LNG exporter-in-waiting and downgraded the stock.
Here's Why Puma Biotechnology Fell 24.1% in July
Investors aren't very optimistic heading into the second-quarter 2019 earnings report. Can the company prove critics wrong?
Here's Why Zynerba Pharmaceuticals Lost 21.8% in July
The stock cooled off along with its cannabis-based peers.
Codexis Rolls Into Second Half Armed with Cash
The enzyme engineering platform has $93 million in cash and no shortage of growth opportunities. Can it execute?
Where Will Beyond Meat Be in Five Years?
Can the animal-free protein developer surpass $1 billion in annual revenue by the end of 2024?
Kala Pharmaceuticals Reports Disappointing Q2 Sales
The company finally has a drug product on the market, but it didn't live up to Wall Street's expectations in the second quarter.
Zoetis Keeps Growing, but Headwinds Persist
Spending is taking a bite out of the bottom line, and livestock products continue to perform poorly, but that didn't keep the animal health leader from increasing its outlook for the year.
Tandem Diabetes Care Raises Full-Year 2019 Revenue Guidance to $358 Million
The medical device company got oh-so-close to erasing operating losses in Q2, but second-half growth will finally put the business in the black.
Where Will Viking Therapeutics Be in 1 Year?
It's one of the more promising companies in the race to develop a successful NASH treatment. Will patient investors be rewarded?
Here's Why Genetic Testing Stocks Rose as Much as 25.4% in July
It was a great month to be a genetic testing company.
Fluidigm is Running in Place, but Expects to Break Out in 2020
Weakness in the legacy microfluidics business is offsetting the company's best growth opportunity. What needs to happen for that to change?
Vanda Pharmaceuticals Returns to Profitability in Q2
The stock popped after the company reported a solid quarter of operations, but serious red flags remain.
Here's Why Nektar Therapeutics Declined 20% in July
The company can't seem to sustain any momentum.
Here's Why Galapagos NV Rose 34.5% in July
The Belgian biopharma bagged $5.1 billion from its most important partner.
Here's Why Illumina Tumbled 18.7% in July
Growth stagnated in the first half of 2019. Management says it will be temporary.
Repligen Grows Revenue 48% in Q2
The bioprocess leader keeps growing at an incredible pace thanks to acquisitions and surging customer demand.
Here's Why Cara Therapeutics Rose 11.3% in July
The development-stage pharma company started an important clinical trial.
Is Green Plains a Buy?
Shares look awfully cheap, but there's a good reason for that.
1 Stat Shows Coal-Fired Power Plants Have Passed the Point of No Return
Coal-fired power plants are doing something most of us can only dream of: retiring at the age of 46 years.